Loading…
← CockpitCompetitor Analysis › 300146.SZ By-health Co., Ltd. Class AOpen in the cockpit ↗

By-health Co., Ltd. Class A300146.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Other

China's leading branded dietary-supplement maker, selling vitamins, protein powders and other nutrition products.

≈ A Chinese GNC/Nature's BountyMomentum leader 91
Mkt cap
$2.56B
US dollars, full cap
Free float
71%
of shares outstanding
$/day
$22.3M
20-day average traded
Fwd P/E
24.7×
forward earnings
ROIC−WACC
+2.5 pp
WACC 7.6%
Hurdle
+4 pp
Req g minus delivered
Next earnings
124 days
22 Mar 2027
Close · CNYCN¥10.08
1D-0.9%
1W-0.7%
1M+5.5%
3M0.0%
6M-0.9%
YTD-16.1%
1Y-19.7%
ATR %2.0%
52w lowhigh23.0% off high

What By-health does

China's leading branded dietary-supplement maker, selling vitamins, protein powders and other nutrition products.

A large share of sales goes through online shops and platforms and through pharmacy and retail channels, with marketing spend a major cost. Life-Space, an Australian probiotics brand it acquired, gives it a probiotic line from outside China.

In one line: A Chinese GNC/Nature's Bounty.

Products and services

  • Vitamins and mineral supplements
  • Protein and sports nutrition products
  • Probiotic supplements

Customers

  • Retail and e-commerce consumers

Where it sits in the supply chain

  • Consumer health
  • Dietary supplements
  • Vitamins and nutrition products

What could go right

  • Rising Chinese health/wellness spending
  • E-commerce channel growth

What could go wrong

  • Direct-selling and e-commerce competition
  • Regulatory scrutiny of health claims

Moat: narrow (brand, distribution). Leading domestic supplement brand with wide pharmacy, retail and e-commerce distribution.

Headquarters: Zhuhai, China · Founded: 1995 · Employees: 3,049

Named competitors

By-health at a glance

Size By-health (300146.SZ) is a China Health Care company (Pharmaceuticals: Other) with a market value of $2.56B, the 926th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥10.08 on 18 Nov 2026.

Performance Over six months the shares fell 0.9%, against -0.8% for the median peer and -20.0% for the China market (cap-weighted) — 11th highest of 21 in its peer set.

Growth Revenue grew 10.4% over the last twelve months (peer median +9.1%); the operating margin is 11.1% (peer median 16.4%).

Valuation It trades at 24.7× forward earnings against a peer median of 17.0× (6th most expensive of 17).

Price implies For today's price to make sense, revenue must grow about 5% a year for seven years (Req g). Recent delivered growth is +1%, so the hurdle is +4 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 2.5 points above its cost of capital (7.6% WACC).

Next results Next results expected around 22 Mar 2027 (exchange calendar; dates can move).

Relative performance

9010011021 May 202621 Aug 202618 Nov 2026Peer median 101300146.SZ 100
Six months, rebased to 100: By-health against the median of its 20 peers (local-currency closes).

By-health financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥6.65BCN¥6.22BCN¥6.81BCN¥9.31BCN¥7.80B
Revenue growth—-9%-27%+19%—
Gross profitCN¥4.66BCN¥4.02BCN¥4.36BCN¥6.23BCN¥5.14B
EBITDAn/aCN¥1.18BCN¥999MCN¥2.10BCN¥1.80B
Net incomeCN¥688MCN¥782MCN¥653MCN¥1.75BCN¥1.39B
Free cash flowCN¥628MCN¥1.24BCN¥461MCN¥885MCN¥1.27B
Capital expenditureCN¥121MCN¥133MCN¥306MCN¥1.26BCN¥245M
Total debtCN¥1.18BCN¥1.03BCN¥1.57BCN¥174MCN¥24.3M

Quarterly statements and history in the cockpit →

By-health competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%0%+20%6000626007500006230023171112GRANULESBHC600056300363600216SUDEEPPHRMJWEL0004236472PHMCRON2142300146.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. By-health is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%+60%0×50×6000626007500023171112GRANULESBHC002603600216SUDEEPPHRMJWEL000423BIOG-BPHMCRON2142300146.SZRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. By-health is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%+60%0%25%50%600062600750000623002317GRANULESBHC600056300363JWEL0004236472PHMCRON2142300146.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. By-health is the large dot.

By-health competitors and peer comparison

Head to head with its named competitors (300146.SZ vs HLF vs 1112.HK vs USNA)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
By-health 300146.SZ$2.56B-1%+10%11%24.7×4.8%
Herbalife HLF$1.68B+28%+6%9%5.7×-14.2%
Health and Happiness (H&H) International 1112.HK$2.15B+108%+24%16%13.2×-1.7%
USANA Health Sciences USNAn/a-27%n/an/an/an/a
Jamieson Wellness JWEL.TO$1.32B+32%+12%13%20.6×13.5%

How By-health compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

By-health against its 20 peers (data as of 18 Nov 2026)
Measure300146.SZPeer medianRank in peer set
1-month return+5.5%-1.3%5th highest of 21
6-month return-0.9%-0.8%11th highest of 21
Distance from 52-week high-23.0%-23.0%11th highest of 21
Revenue growth (TTM)+10.4%+9.1%10th highest of 21
Operating margin11.1%16.4%7th lowest of 21
Forward P/E24.7×17.0×6th most expensive of 17
Growth the price implies (Req g, 7 yrs)4.8%1.5%8th most demanding of 20
Growth delivered (Del g)+0.6%+10.4%4th lowest of 20
Hurdle (Req g minus delivered)+4.2 pp-8.3 pp4th most demanding of 20
ROIC minus cost of capital+2.5 pp+4.1 pp9th lowest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
By-health 300146.SZChina$2.56B-1%+10%11%24.7×4.8%+0.6%
China Resources Double-Crane Pharmaceutical 600062.SSChina$2.35B-14%-1%13%9.3×-9.1%+5.3%
China Resources Jiangzhong Pharmaceutical 600750.SSChina$2.27B+4%-10%24%16.5×-1.9%+11.6%
Jilin Aodong Pharmaceutical 000623.SZChina$2.97B-7%-4%-13%n/a5.0%+1.0%
Guangdong Zhongsheng Pharmaceutical 002317.SZChina$3.00B+11%-14%9%91.7×33.8%+5.9%
Health and Happiness (H&H) International 1112.HKHong Kong$2.15B+108%+24%16%13.2×-1.7%+4.4%
Granules India GRANULES.NSIndia$2.12B+4%+22%17%24.8×23.6%+10.6%
Bausch Health Companies BHC.TOCanada$3.27B+66%+10%27%2.0×-14.8%+5.9%
China Meheco 600056.SSChina$1.90B-16%+2%3%n/a-1.3%-2.1%
Shijiazhuang Yiling Pharmaceutical 002603.SZChina$3.83B-7%+32%21%17.5×-3.9%-2.2%
Porton Pharma Solutions 300363.SZChina$1.66B+37%+6%-2%n/a2.1%+10.4%
Tibet Cheezheng Tibetan Medicine 002287.SZChina$1.58B-17%-7%28%n/a-1.9%+10.4%
Zhejiang Medicine 600216.SSChina$1.51B-26%-6%7%11.5×-7.8%+3.9%
Sudeep Pharma SUDEEPPHRM.NSIndia$1.45B+85%+27%33%69.1×n/an/a
Jamieson Wellness JWEL.TOCanada$1.32B+32%+12%13%20.6×13.5%+15.3%
Dong-E-E-Jiao 000423.SZChina$4.99B+1%+8%29%17.8×-3.7%+14.5%
Bora Pharmaceuticals 6472.TWTaiwan$1.25B-2%+7%14%10.8×3.5%+60.2%
BioGaia BIOG-B.STSweden$1.25B-4%+13%28%31.0×1.5%+15.5%
Pharma Mar PHM.MCSpain$1.21B-38%+32%19%41.4×10.6%-3.9%
Cronos CRON.TOCanada$1.17B+24%+55%5%16.2×18.8%+26.7%
HBM 2142.HKHong Kong$1.12B-18%+55%44%11.7×13.1%+62.3%

Questions

Who are By-health's main competitors?
Named competitors: Herbalife (HLF), Amway (Nutrilite) (private or unlisted), H&H Group (1112.HK), USANA Health Sciences (USNA), Nu Skin Enterprises (private or unlisted), Jamieson Wellness (JWEL.TO). The cockpit's measured peer set (industry) also includes China Resources Double-Crane Pharmaceutical (600062.SS), China Resources Jiangzhong Pharmaceutical (600750.SS), Jilin Aodong Pharmaceutical (000623.SZ), Guangdong Zhongsheng Pharmaceutical (002317.SZ), Health and Happiness (H&H) International (1112.HK), Granules India (GRANULES.NS).
Is By-health expensive compared with its peers?
On forward p/e it trades at 24.7× against a peer median of 17.0×, 6th most expensive of 17 in its peer set. For today's price to make sense, revenue must grow about 5% a year for seven years (Req g). Recent delivered growth is +1%, so the hurdle is +4 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has By-health stock performed?
Over six months to 18 Nov 2026 the shares returned -0.9% against -0.8% for the median peer; over one year -19.7%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.